SignalFDA/Bio

European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status

EU approval expands Trodelvy’s first-line use across all PD-L1 statuses, boosting market access.

What changed

EU approval expands Trodelvy’s first-line use across all PD-L1 statuses, boosting market access.

Why it matters

EU approval expands Trodelvy’s first-line use across all PD-L1 statuses, boosting market access. — impact context not separately stored; see What changed.

Sources

eodhd